In a population-based Swedish OPT trial of 13,000+ 50-year-old men, a PSA→Stockholm3 reflex pathway was linked to 64% fewer prostate MRIs and 33% fewer biopsies vs PSA-based screening alone. Findings were presented at EAU 2026 (Abstract A0413: “Stockholm3 Test Performance for Reducing MRI in Organised Prostate Cancer Testing (OPT)”).

Why It Matters To Your Practice

• Prostate MRI capacity is a common bottleneck; cutting MRI referrals by ~64% can ease scheduling delays and downstream workflow strain.

• Reflex biomarker triage after an elevated PSA may reduce unnecessary escalation while preserving focus on men most likely to benefit from imaging and biopsy.

• The approach fits organized screening pathways and may be adaptable to local protocols where PSA alone drives high imaging volume.

Clinical Benefits

• Resource reduction: MRI use fell ~64% and biopsies ~33% when MRI referral required Stockholm3 ≥15 after PSA ≥2 ng/mL.

• Operational efficiency: fewer MRIs and biopsies can translate to fewer procedure-related visits, less patient churn, and reduced follow-up burden.

• Potential further streamlining: using a higher PSA threshold (>3 ng/mL) for reflex testing was reported to reduce Stockholm3 tests and MRIs even more (68% MRI reduction) without missing higher-grade cancers in this early analysis.

Managing Risks

• Cancer detection tradeoff: detection of both low-grade and clinically significant prostate cancer was slightly lower, with imprecise estimates—counsel patients that risk reduction in procedures may come with uncertainty about delayed detection.

• Protocol clarity is key: ensure your pathway defines PSA thresholds, Stockholm3 cutoff (≥15 in this report), and MRI/biopsy triggers to avoid inconsistent referrals.

• Follow-up and safety netting: plan repeat PSA/testing intervals and clear re-evaluation criteria, especially for men near thresholds or with persistent symptoms/risk factors.

The Bottom Line

• A PSA→Stockholm3 reflex strategy in 13,000+ screened men was linked to substantially fewer MRIs (64%) and biopsies (33%) vs PSA-only screening.

• Expect meaningful relief of imaging/procedure demand, but watch for potential detection tradeoffs and prioritize standardized pathways and follow-up.